BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20197765)

  • 1. A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo.
    Hovland S; Arbyn M; Lie AK; Ryd W; Borge B; Berle EJ; Skomedal H; Kadima TM; Kyembwa L; Billay EM; Mukwege D; Chirimwami RB; Mvula TM; Snijders PJ; Meijer CJ; Karlsen F
    Br J Cancer; 2010 Mar; 102(6):957-65. PubMed ID: 20197765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
    Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
    J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.
    Ovestad IT; Vennestrøm U; Andersen L; Gudlaugsson E; Munk AC; Malpica A; Feng W; Voorhorst F; Janssen EA; Baak JP
    Gynecol Oncol; 2011 Nov; 123(2):278-83. PubMed ID: 21835440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
    Wang HY; Lee D; Park S; Kim G; Kim S; Han L; Yubo R; Li Y; Park KH; Lee H
    Asian Pac J Cancer Prev; 2015; 16(17):7633-40. PubMed ID: 26625774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.
    Varnai AD; Bollmann M; Bankfalvi A; Speich N; Schmitt C; Griefingholt H; Kovács K; Klozoris C; Bollmann R
    Oncol Rep; 2008 Feb; 19(2):457-65. PubMed ID: 18202795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.
    Duvlis S; Popovska-Jankovic K; Arsova ZS; Memeti S; Popeska Z; Plaseska-Karanfilska D
    J Med Virol; 2015 Sep; 87(9):1578-86. PubMed ID: 25880030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
    Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.
    Andersson E; Kärrberg C; Rådberg T; Blomqvist L; Zetterqvist BM; Ryd W; Lindh M; Horal P
    J Clin Microbiol; 2011 Nov; 49(11):3794-9. PubMed ID: 21940473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA.
    Coquillard G; Palao B; Patterson BK
    Gynecol Oncol; 2011 Jan; 120(1):89-93. PubMed ID: 20950847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
    Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
    J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
    Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
    J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.
    Alaghehbandan R; Fontaine D; Bentley J; Escott N; Ghatage P; Lear A; Coutlee F; Ratnam S
    Diagn Cytopathol; 2013 Sep; 41(9):767-75. PubMed ID: 23341349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.